L-asparaginase treatment in acute lymphoblastic leukemia

Cancer

Volumn 117, Issue 2, 2011, Pages 238-249

  Pieters, Rob ^a   Hunger, Stephen P ^b   Boos, Joachim ^c   Rizzari, Carmelo ^d   Silverman, Lewis ^e   Baruchel, Andre ^f   Goekbuget, Nicola ^g   Schrappe, Martin ^h   Pui, Ching Hon ⁱ  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b University of Colorado Denver and Children s Hospital Colorado   (United States)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d SAN GERARDO HOSPITAL   (Italy)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f SAINT LOUIS HOSPITAL   (France)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

acute lymphoblastic leukemia; ALL; asparaginase; asparagine depletion; Erwinase; Erwinia asparaginase

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; DEXAMETHASONE; DRUG ANTIBODY; LIVER ENZYME; PREDNISOLONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANAPHYLAXIS; BLEEDING; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG MONITORING; EDEMA; ERWINIA; ERYTHEMA; ESCHERICHIA COLI; EVENT FREE SURVIVAL; HEMOSTASIS; HUMAN; HYPERGLYCEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIPID METABOLISM; LIVER TOXICITY; LYMPHOBLASTOMA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PAIN; PANCREATITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RECURRENCE RISK; RETREATMENT; REVIEW; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOSIS; TREATMENT DURATION; URTICARIA;

ASPARAGINASE; DRUG COMBINATIONS; DRUG HYPERSENSITIVITY; DRUG MONITORING; ERWINIA; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SPIRONOLACTONE; SULFONAMIDES;

EID: 78650976352     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25489     Document Type: Review

References (73)

1. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia 1981-1995. Leukemia. 2000; 14: 2247-2256.
2. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001; 97: 1211-1218.
3. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004; 104: 2690-2696.
4. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009; 360: 2730-2741.
5. Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008; 111: 4477-4489.
6. Pieters R, Carroll WL,. Biology and treatment of acute lymphoblastic leukemia. Pediatr Clin North Am. 2008; 55: 1-20.
7. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone Hyper-CVAD., a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004; 101: 2788-2801.
8. Goekbuget N, Baumann A, Beck J, et al. PEG-asparaginase in adult acute lymphoblastic leukemia ALL: efficacy and feasibility analysis with increasing dose levels. Blood. 2008; 112. Abstract 302.
9. de Bont JM, Holt B, Dekker AW, van der Does-van den Berg, Sonneveld P, Pieters R,. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004; 18: 2032-2035.
10. Schiffer CA,. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol. 2003; 21: 760-761.
11. Pui CH, Robison LL, Look AT,. Acute lymphoblastic leukaemia. Lancet. 2008; 371: 1030-1043.
12. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003; 21: 774-780.
13. Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D,. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009; 27: 2269-2277.
14. Huguet F, Raffoux E, Thomas X, et al. Towards a pediatric approach in adults with acute lymphoblastic leukemia ALL.: the GRAALL-2003 Study. Blood. 2006; 108. Abstract 147.
15. Storring JM, Brandwein J, Gupta V, et al. Treatment of adult acute lymphoblastic leukemia ALL. with a modified DFCI pediatric regimen-The Princess Margaret Experience. Blood. 2006; 108. Abstract 1875.
16. Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric ALL97. and adult UKALLXII/E2993. trials. Pediatr Blood Cancer. 2006; 48: 254-261.
17. Linker C, Damon L, Ries C, Navarro W,. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002; 20: 2464-2471.
18. Avramis VI, Tiwari PN,. Asparaginase native ASNase or pegylated ASNase. in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine. 2006; 1: 241-254.
19. Oncospar. Summary of Product Characteristics. Sigma-Tau Pharmaceuticals, Inc. 2006.
20. Pieters R, Appel I, Kuehnel HJ, et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. Blood. 2008; 112: 4832-4838.
21. Bertrand Y, Thomas X, Baruchel A, et al. GRASPALL 2005.01 Clinical Study L-asparaginase loaded into red blood cells is effective at depleting serum asparagine in children and adults with relapsed acute lymphoblastic leukaemia ALL. Blood. 2008; 112. Abstract 306.
22. Allas S, Sahakian P, Fichtner I, Abribat T,. Pharmacokinetics and pharmacodynamics in mice of a pegylated recombinant Erwinia Chrysanthemi-derived l-asparaginase. Blood. 2009; 114. Abstract 2033.
23. Miller HK, Salser JS, Balis ME,. Amino acid levels following L-asparagine amidohydrolase EC. 3.5.1.1. therapy. Cancer Res. 1969; 29: 183-187.
24. Avramis VI, Martin-Aragon S, Avramis EV, Asselin BL,. Pharmacoanalytical assays of Erwinia asparaginase Erwinase. and pharmacokinetic results in high-risk acute lymphoblastic leukemia HR ALL. patients: simulations of Erwinase population PK-PD models. Anticancer Res. 2007; 27: 2561-2572.
25. Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer. 1996; 32A: 1544-1550. (Pubitemid 26279122)
26. Vieira Pinheiro JP, Ahlke E, Nowak-Gottl U, et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol. 1999; 104: 313-320.
27. Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 2008; 22: 1665-1679.
28. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002; 99: 1986-1994.
29. Ollenschlager G, Roth E, Linkesch W, Jansen S, Simmel A, Modder B,. Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur J Clin Invest. 1988; 18: 512-516.
30. Broome JD,. L-Asparaginase: discovery and development as a tumor-inhibitory agent. Cancer Treat Rep. 1981; 65 (suppl 4): 111-114.
31. Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R,. FDA drug approval summary: pegaspargase Oncaspar. for the first-line treatment of children with acute lymphoblastic leukemia ALL. Oncologist. 2007; 12: 991-998.
32. Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol. 1997; 96: 675-681.
33. Vieira Pinheiro JP, Wenner K, Escherich G, et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m2. PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer. 2006; 46: 18-25.
34. Liang DC, Hung IJ, Yang CP, et al. Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan Pediatric Oncology Group. Leukemia. 1999; 13: 155-160.
35. Ertel IJ, Nesbit ME, Hammond D, Weiner J, Sather H,. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Children's Cancer Study Group. Cancer Res. 1979; 39: 3893-3896. (Pubitemid 10242204)
36. Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986; 315: 657-663.
37. Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E, 3rd, Nathan DG,. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983; 43: 5601-5607.
38. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999; 13: 335-342.
39. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 2002; 99: 2734-2739.
40. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007; 109: 896-904.
41. Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005; 23: 7161-7167.
42. Rizzari C, Valsecchi MG, Arico M, et al. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Munster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia studya a report from the Associazione Italiana Ematologia Oncologia Pediatrica. J Clin Oncol. 2001; 19: 1297-1303.
43. Albertsen BK, Schroder H, Jakobsen P, Muller HJ, Carlsen NT, Schmiegelow K,. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmacol. 2001; 52: 433-437.
44. Rizzari C, Zucchetti M, Conter V, et al. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol. 2000; 11: 189-193.
45. Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004; 26: 217-226.
46. Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000; 18: 1525-1532.
47. Larson RA, Fretzin MH, Dodge RK, Schiffer CA,. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia. 1998; 12: 660-665.
48. Hawkins DS, Park JR, Thomson BG, et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res. 2004; 10: 5335-5341.
49. Wang B, Relling MV, Storm MC, et al. Evaluation of immunologic cross-reaction of antiasparaginase antibodies in acute lymphoblastic leukemia ALL. and lymphoma patients. Leukemia. 2003; 17: 1583-1588.
50. Albertsen BK, Schroder H, Jakobsen P, et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol. 2002; 38: 310-316.
51. Albertsen BK, Schmiegelow K, Schroder H, et al. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study. Cancer Chemother Pharmacol. 2002; 50: 117-120.
52. Nesbit M, Chard R, Evans A, Karon M, Hammond GD,. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol. 1979; 1: 9-13.
53. Albertsen BK, Schroder H, Ingerslev J, et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol. 2001; 115: 983-990.
54. Barry E, DeAngelo DJ, Neuberg D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol. 2007; 25: 813-819. (Pubitemid 350002881)
55. Asselin BL,. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999; 457: 621-629.
56. Wenner KA, Vieira Pinheiro JP, Escherich G, et al. Asparagine concentration in plasma after 2,500 IU/m2. PEG-asparaginase i.v. in children with acute lymphoblastic leukemia. Klin Padiatr. 2005; 217: 321-326.
57. Hak LJ, Relling MV, Cheng C, et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2004; 18: 1072-1077.
58. Zalewska-Szewczyk B, Andrzejewski W, Mlynarski W, Jedrychowska-Danska K, Witas H, Bodalski J,. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2007; 48: 931-936.
59. Fu CH, Sakamoto KM,. PEG-asparaginase. Expert Opin Pharmacother. 2007; 8: 1977-1984.
60. Zalewska-Szewczyk B, Gach A, Wyka K, Bodalski J, Mlynarski W,. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med. 2009; 9: 113-116.
61. Hempel G, Muller HJ, Lanvers-Kaminsky C, Wurthwein G, Hoppe A, Boos J,. A population pharmacokinetic model for pegylated-asparaginase in children. Br J Haematol. 2010; 148: 119-125.
62. Gadner H, Masera G, Schrappe M, et al. The Eighth International Childhood Acute Lymphoblastic Leukemia Workshop 'Ponte di legno meeting'. report: Vienna, Austria, April 27-28, 2005. Leukemia. 2006; 20: 9-17.
63. Alvarez OA, Zimmerman G,. Pegaspargase-induced pancreatitis. Med Pediatr Oncol. 2000; 34: 200-205.
64. Kearney SL, Dahlberg SE, Levy DE, Voss SD, Sallan SE, Silverman LB,. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2009; 53: 162-167.
65. Parsons SK, Skapek SX, Neufeld EJ, et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood. 1997; 89: 1886-1895.
66. Eden OB, Shaw MP, Lilleyman JS, Richards S,. Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia. Med Pediatr Oncol. 1990; 18: 497-502.
67. Kwok CS, Kham SK, Ariffin H, Lin HP, Quah TC, Yeoh AE,. Minimal residual disease MRD. measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia ALL. Pediatr Blood Cancer. 2006; 47: 299-304.
68. Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010; 54: 199-205.
69. Ogawa C, Ohara A, Manabe A, et al. Treatment outcome of discontinued l-asparaginase in children with standard-risk acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group TCCSG. Study L99-15. Blood 2005; 106. Abstract 878.
70. Schrey D, Borghorst S, Lanvers-Kaminsky C, et al. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 Protocol between 2000 and 2007. Pediatr Blood Cancer. 2010; 54: 952-958.
71. Armstrong JK, Hempel G, Koling S, et al. Antibody against polyethylene glycol. adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007; 110: 103-111.
72. Billett AL, Carls A, Gelber RD, Sallan SE,. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer. 1992; 70: 201-206.
73. Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica. 2006; 91: 24-31.